Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant tislelizumab plus cisplatin and nab-paclitaxel with pathology-guided postoperative stratified therapy in resectable locally advanced HNSCC
ChiCTR2500103027Phase 2Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, cisplatin, paclitaxel and nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by First Hospital of China Medical University. Primary endpoint: 2-year event-free survival rate. Started May 2025; status: recruiting.
02
Drugs
tislelizumabcisplatinpaclitaxelnimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500103027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103027.